🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Alessio Cortellini

Università Campus Bio-Medico

ORCID: 0000-0002-1209-5735

Also affiliated with Campus Bio Medico University Hospital

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 5%percentile
0.427Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008724
Top 44%
0.427DataRank
Top 44%8 citations

Ahmed Bilal Khalid, Serena Rahme, Caiwei Zhong, Lucia Kwak, Marita Salame +28 more

Papers

Driven by 11 papers — median percentile 56. Top paper: “Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis”.

Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis

The Lancet Oncology(2024)10.1016/s1470-2045(24)00457-1
N/A
1.7DataRank · unranked
70 citations

Bernardo Stefanini, Julia Blanter, Benjamin Adegbite, Fionnuala Crowley, Vincent Yip +18 more

Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008724
Top 44%
0.427DataRank
Top 44%8 citations

Ahmed Bilal Khalid, Serena Rahme, Caiwei Zhong, Lucia Kwak, Marita Salame +28 more

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer

Annals of Oncology(2022)10.1016/j.annonc.2022.07.005
N/A
0DataRank · unranked
105 citations

Joao V. Alessi, Arielle Elkrief, Xinan Wang, Alessio Cortellini, Y Y Li +27 more

Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma

Clinical Genitourinary Cancer(2022)10.1016/j.clgc.2022.06.001
N/A
0DataRank · unranked
28 citations

Rafee Talukder, Genevieve Ihsiu Lin, Leonidas Nikolaos Diamantopoulos, Scott J. Dawsey, Shilpa Gupta +47 more

Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma

Clinical Genitourinary Cancer(2022)10.1016/j.clgc.2022.08.006
N/A
0DataRank · unranked
9 citations

Dimitrios Makrakis, Genevieve Ihsiu Lin, Leonidas Nikolaos Diamantopoulos, Scott J. Dawsey, Shilpa Gupta +49 more

A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.01.089
N/A
0DataRank · unranked
78 citations

Haonan Lu, Susan J. Copley, Yidong Han, Andrew Logan, Patrizia Viola +5 more

Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad155
N/A
0DataRank · unranked
56 citations

Amin H. Nassar, Gregory R. Pond, Tony Zhuang, Viraj A. Master, Bassel Nazha +50 more

Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry

International Journal of Infectious Diseases(2023)10.1016/j.ijid.2023.11.021
N/A
0DataRank · unranked
3 citations

Samuel Minkove, Isabel Ruíz-Camps, Simeón Eremiev, Gino M Dettorre, María Laura Fox +39 more

TERAVOLT: Thoracic Cancers International COVID-19 Collaboration

Cancer Cell(2020)10.1016/j.ccell.2020.05.008
N/A
0DataRank · unranked
59 citations

Annalisa Trama, Valter Torri, Alessandro De Toma, Giuseppe Viscardi, Alessio Cortellini +12 more

Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders

JAMA Network Open(2025)10.1001/jamanetworkopen.2025.13727
N/A
0DataRank · unranked
14 citations

Marc Machaalani, Razane El Hajj Chehade, Amin H. Nassar, Rashad Nawfal, Michael P. Manos +20 more

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

European Journal of Cancer(2022)10.1016/j.ejca.2022.08.024
N/A
0DataRank · unranked
112 citations

Jaekyung Cheon, Antonio D’Alessio, Naoshi Nishida, Celina Ang, Thomas U. Marron +32 more